Leaps by Bayer

Indapta Therapeutics is a biotechnology company focused on developing an off-the-shelf, non-engineered NK (natural killer) cell therapy platform for treating blood and solid tumor cancers. The company aims to enhance the immune response and improve antibody therapy cytotoxicity.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

Jixing Pharmaceuticals is a global biotechnology company focused on developing and commercializing innovative therapeutics for cardiovascular and ophthalmic diseases. The company’s asset pipeline includes treatments for conditions such as hypertrophic cardiomyopathy, heart failure, presbyopia, hypertension, and dry eye disease. Jixing Pharmaceuticals has in-licensed a small molecule cardiac myosin inhibitor, designed to address the specific needs of patients suffering from hypertrophic cardiomyopathy. By providing advanced treatment options, the company aims to meet the significant unmet medical needs of patients in China and beyond, particularly those facing serious, life-threatening health challenges in the fields of cardiology and ophthalmology.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Paratus Sciences focuses on advancing human health and health security by studying the biology of bats. It integrates cell biology, genomics, informatics, and large-scale data inputs to compare disease resistance patterns in bats with those in humans, aiming to develop therapeutics that mimic bats' adaptations.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Founded in 2013, Sound Agriculture develops crop enhancement products using molecular discovery. Their solutions aim to increase harvest yields, enhance water efficiency, and improve crop resilience to climate change.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Indapta Therapeutics is a biotechnology company focused on developing an off-the-shelf, non-engineered NK (natural killer) cell therapy platform for treating blood and solid tumor cancers. The company aims to enhance the immune response and improve antibody therapy cytotoxicity.

Gandeeva Therapeutics is a precision biotechnology company that combines cryogenic electron microscopy (cryo-EM) and machine learning to discover and develop therapeutics by targeting and modulating key protein-protein interactions. Its structure-guided drug discovery platform comprises SPOTLIGHT for target prediction and validation, HYPERFOCUS for hit identification from virtual and fragment libraries, and CRYO-CADD for lead optimization. The company pursues a preclinical oncology program focused on difficult-to-treat cancers with novel protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area of Canada, Gandeeva aims to advance differentiated therapeutics and improve outcomes for patients by leveraging its integrated imaging, modeling, and screening capabilities.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Bloom Science is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapeutics for neurological disorders. It employs a gut-brain axis approach through its IrisRx platform to discover and design medicines from gut microbes using synthetic biology, aiming for novel biology and improved safety profiles. The company seeks to translate the therapeutic benefits associated with the ketogenic diet into medicines that treat epilepsy and other central nervous system conditions. Its pipeline encompasses therapies for Dravet syndrome and other rare epilepsies, as well as Amyotrophic Lateral Sclerosis and other neurodegenerative and cognitive disorders. Bloom Science pursues translational research to advance microbe-based therapeutics that address unmet needs in neurology. The company is headquartered in San Diego, California.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Founded in 2013, Sound Agriculture develops crop enhancement products using molecular discovery. Their solutions aim to increase harvest yields, enhance water efficiency, and improve crop resilience to climate change.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Edifice Health is a biotechnology company spun out from Stanford University's 10-year research study on immune profiling. It offers the first biomarker composite scoring system, Inflammatory Age®, which predicts chronic diseases and provides insights to help individuals manage their aging process.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

Joyn Bio LLC, established in 2017, is a Boston-based joint venture between Leaps by Bayer and Ginkgo Bioworks, Inc., with a plant research facility in West Sacramento, California. The company specializes in developing probiotics for plants using synthetic biology, aiming to provide cereal crops like corn, wheat, and rice with their nitrogen needs, thereby reducing agriculture's reliance on chemical fertilizers and mitigating environmental impacts. Joyn Bio's team comprises microbiologists, synthetic biologists, plant scientists, and ecologists working collaboratively to address these challenges.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.